Todd Bazemore
Independent DirectorMr. Todd Bazemore is CEO, President & Director of AIRNA Corporation from June 2026. Mr. Todd Bazemore was Interim CEO of KALA BIO, Inc. from February 11, 2025 to September 2025 and served as its Chief Executive Officer since September 2025 until October 19, 2025 and was its Director since September 2025 until January 30, 2026. Mr. Bazemore served as the Chief Operating Officer of KALA BIO, Inc. (formerly known as Kala Pharmaceuticals, Inc.) since November 20, 2017 until September 2025 and served as its President since December 16, 2021 until October 19, 2025 and was its Principal Executive Officer from October 19, 2025 to January 30, 2026. Mr. Bazemore served as Chief Operating Officer and Executive Vice President of Santhera Pharmaceuticals (USA) Inc. (subsidiary of Santhera Pharmaceuticals Holdings AG) from September 2016 to November 2017. Mr. Bazemore joined Dyax as a pharmaceutical executive of leadership and commercial operating experience in sales, marketing and managed markets. Between April 2012 and September 2013, he served as Vice President of Managed Markets at Sunovion Pharmaceuticals, Inc. (formerly Sepracor), (now Dainippon Sumitomo Pharma Co. Ltd.) Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of the Respiratory Business Unit. At Dyax, Mr. Bazemore oversaw all aspects of Dyax?s commercial department including sales, marketing, commercial analytics, market access and patient services. Prior to joining Santhera, Mr. Bazemore was Chief Commercial Officer and Executive Vice President of Dyax Corp. since April 2014 until January 22, 2016. he was responsible for global commercial strategy and oversight of all commercial functions up until Dyax was acquired by Shire plc. Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Business Unit. During his time at Sunovion, Mr. Bazemore held several roles of increasing responsibility in marketing and sales leadership including Vice President of Sales for the Pinnacle Sales Team, which was responsible for promoting OMNARIS(R), as well as LUNESTA(R), one of the most successful pharmaceutical product launches in the U.S. He serves as Advisor of Mahana Therapeutics, Inc. He also went on to build and oversee multiple sales and marketing teams responsible for several successful new product launches including BROVANA(R) and XOPENEX(R). He has been an Independent Director of Pulmatrix, Inc. since October 1, 2020. He received his Bachelor of Science from the University of Massachusetts, Lowell.
Positions
- Company NamePulmatrix, Inc.Stock CodePULMPositionIndependent Director
